title: Ductal carcinoma in situ.
abstract: Management of ductal carcinoma in situ (DCIS) has evolved from radical surgery to the option of a more minimally invasive approach. Data show that breast conservation surgery performed with administration of radiotherapy, like mastectomy, is feasible and safe. Because efforts to find a safe group for elimination of radiotherapy have resulted in data that conflict, radiotherapy still remains standard of care as a part of breast conservation for DCIS. Tamoxifen has also shown a significant recurrence benefit and has become standard in the treatment of receptor-positive disease. Investigation of other agents, such as anastrazole and trastuzumab, are ongoing.
authors: Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Room C-308, Philadelphia, PA 19111, USA. richard.bleicher@fccc.edu
authors: Richard J
authors: RJ
authors: Bleicher
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000628:therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000175:diagnosis / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D018714:Radiotherapy, Adjuvant; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen